See the DrugPatentWatch profile for Mircera
What is Mircera, and what injections is it used for?
Mircera (methoxy polyethylene glycol-epoetin beta) is an injection used to treat anemia caused by reduced kidney function (chronic kidney disease). It is given to help raise hemoglobin and reduce the need for blood transfusions in people who have anemia from kidney disease [1].
How is Mircera typically used in patients with kidney disease?
In clinical use, Mircera is prescribed for:
- Anemia in adults with chronic kidney disease, including patients on dialysis and patients not on dialysis [1].
How is Mircera given (what “uses” it in practice)?
Mircera is administered as an injection, typically by healthcare professionals. It may be given either:
- Subcutaneously (under the skin), or
- Intravenously (into a vein) [1].
Does Mircera have other uses beyond kidney-related anemia?
Based on the provided information, Mircera’s established use is for anemia due to chronic kidney disease. Other off-label uses are not specified here [1].
What should patients watch for after starting Mircera?
Because Mircera works to raise hemoglobin, it can carry risks associated with erythropoiesis-stimulating agents. The prescribing information includes safety guidance, but specific side effects and monitoring details aren’t included in the provided source text [1].
Sources
- https://www.medicines.org.uk/emc/product/1132/smpc